{"filing":{"accession_number":"0001628280-26-049499","cik":"0001706431","ticker":"VIR","company_name":"Vir Biotechnology, Inc.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-20","primary_document":"vir-20260720.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026049499/vir-20260720.htm"},"events":[{"id":20332,"run_id":18306,"accession_number":"0001628280-26-049499","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Jason O'Byrne, Executive Vice President and Chief Financial Officer, is stepping down effective August 3, 2026, to pursue another opportunity. While the filing also discloses the appointment of Brent Sabatini as interim principal financial officer, the principal disclosed action centers on the departure of the CFO, a named executive officer. The CFO departure is the material event driving the filing.","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19661,"accession_number":"0001628280-26-049499","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Jason O'Byrne, Executive Vice President and Chief Financial Officer, is stepping down effective August 3, 2026, to pursue another opportunity. While the filing also discloses the appointment of Brent Sabatini as interim principal financial officer, the principal disclosed action centers on the departure of the CFO, a named executive officer. The CFO departure is the material event driving the filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T12:32:35.900416+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19661,"accession_number":"0001628280-26-049499","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Jason O'Byrne, Executive Vice President and Chief Financial Officer, is stepping down effective August 3, 2026, to pursue another opportunity. While the filing also discloses the appointment of Brent Sabatini as interim principal financial officer, the principal disclosed action centers on the departure of the CFO, a named executive officer. The CFO departure is the material event driving the filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T12:32:35.900416+00:00","company_name":"Vir Biotechnology, Inc.","ticker":"VIR","filing_date":"2026-07-24"}]}